melanoma
Bristol Myers Squibb’s Opdualag Fails Phase 3 Trial in Adjuvant Melanoma Treatment
Opdualag, Bristol Myers Squibb, melanoma, clinical trial failure, LAG-3 inhibitor, immunotherapy, adjuvant treatment
Immatics Advances Melanoma T-Cell Therapy into Late-Stage Clinical Trials
Immatics, melanoma, T-cell therapy, ACTengine IMA203, late-stage clinical trials, SUPRAME Phase 3 trial
BioNTech and Regeneron Achieve Significant Response Rate Success in Phase 2 Trial for mRNA Cancer Immunotherapy BNT111
BioNTech, Regeneron, mRNA immunotherapy, BNT111, Phase 2 trial, melanoma, cancer treatment, PD-1 checkpoint inhibitor, cemiplimab, FixVac platform, uridine mRNA-LPX technology
BioNTech and Regeneron’s mRNA Cancer Vaccine Combo Clears Phase II in Melanoma
BioNTech, Regeneron, mRNA cancer vaccine, Phase II trial, melanoma, BNT111, cemiplimab, Libtayo
iOnctura Secures €80 Million in Series B Financing to Advance Rare Eye Cancer Treatment
iOnctura, Series B financing, rare eye cancer, uveal melanoma, roginolisib, cancer treatment
Moderna and Merck’s Cancer Vaccine Shows Promising Results in Combination with Keytruda
Moderna, Merck, Cancer Vaccine, Keytruda, Melanoma, mRNA Technology, ASCO, FDA, Rare Disease, START Pilot Program